title: A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.
abstract: BACKGROUND
  Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are expressed in a variety of cells, including keratinocytes and cells of the immune system. The gamma subtype, activated by the antidiabetic thiazolidinediones, was originally identified as a regulator of adipogenesis and glucose homeostasis. Recent data, however, have linked PPAR-gamma to several genes involved in inflammation. Among others, these pathways reduce certain inflammatory mediators in the skin and regulate epidermal barrier homeostasis, alterations of which contribute to the inflammation associated with atopic dermatitis (AD). To our knowledge, the addition of rosiglitazone maleate to the standard treatment of AD has not been evaluated.
  
  
  METHODS
  Severe adverse events were not observed, although 1 patient experienced weight gain. All patients responded to rosiglitazone therapy with decreased total body surface area involvement, severity of lesions, and number of flares.
  
  
  CONCLUSIONS
  Rosiglitazone, a drug that has an excellent safety profile, may offer a well tolerated systemic treatment option for AD. However, its role should be further assessed in controlled trials to establish its efficacy and safety in this disease.
authors.affiliation: Department of Dermatology, University Hospitals Case Medical Center, 11100 Euclid Ave, Cleveland, OH 44106-5028, USA.
authors.forename: Ramona
authors.initials: R
authors.lastname: Behshad
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Cooper
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Korman
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000485:Allergens; D003876:Dermatitis, Atopic / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D047495:PPAR gamma / Q000819:agonists*; D010328:Patch Tests / Q000379:methods; D017060:Patient Satisfaction; D012189:Retrospective Studies; D012307:Risk Factors; D000077154:Rosiglitazone; D012494:Sampling Studies; D012720:Severity of Illness Index; D045162:Thiazolidinediones / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone